G01N 33/57585
Involving compounds identifiable in body fluids
Official title: {involving compounds identifiable in body fluids}
G01N33/57585 (Involving compounds identifiable in body fluids) appears on 796 US grants and 2,009 published applications in this corpus.
Search patents in G01N- Granted patents
- 796
- Published applications
- 2,009
- Assignees
- 865
- Inventors
- 3,126
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 3 | 0 |
| 1987 | 3 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 8 | 0 |
| 1994 | 5 | 0 |
| 1995 | 7 | 0 |
| 1996 | 7 | 0 |
| 1997 | 13 | 0 |
| 1998 | 19 | 0 |
| 1999 | 19 | 0 |
| 2000 | 6 | 0 |
| 2001 | 7 | 3 |
| 2002 | 8 | 21 |
| 2003 | 7 | 489 |
| 2004 | 5 | 29 |
| 2005 | 7 | 37 |
| 2006 | 14 | 66 |
| 2007 | 45 | 32 |
| 2008 | 52 | 26 |
| 2009 | 15 | 42 |
| 2010 | 28 | 58 |
| 2011 | 18 | 43 |
| 2012 | 16 | 37 |
| 2013 | 24 | 43 |
| 2014 | 27 | 86 |
| 2015 | 29 | 80 |
| 2016 | 37 | 83 |
| 2017 | 35 | 75 |
| 2018 | 28 | 75 |
| 2019 | 42 | 69 |
| 2020 | 40 | 93 |
| 2021 | 33 | 89 |
| 2022 | 37 | 94 |
| 2023 | 30 | 90 |
| 2024 | 44 | 90 |
| 2025 | 31 | 90 |
| 2026 | 27 | 69 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Diagnosis, prognosis and treatment of malignant neoplasms29 Sep 2026US 12,748,114 B2Rhode Island Hospital
- Cancer diagnostic15 Sep 2026US 12,736,537 B2The Council of the Queensland Institute of Medical Research
- Artificial intelligence for early cancer detection8 Sep 2026US 12,730,108 B2Regents of the University of Minnesota
- Highly sensitive platform to characterize extracellular vesicular biomarkers for cancer immunotherapy1 Sep 2026US 12,724,032 B2OHIO STATE INNOVATION FOUNDATION and SPOT BIOSYSTEMS LTD.
- Methods for photoimmunotherapy and related biomarkers11 Aug 2026US 12,704,501 B2Rakuten Medical, Inc.
- Combination therapy of polio virus receptor inhibitors and fucose8 Oct 2026US 2026/0309713 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Human anti-fgf2 monoclonal antibody (mab), pharmaceutical composition comprising same, use thereof and kit for the detection of cancer in a biological sample comprising said mab1 Oct 2026US 2026/0297170 A1Instituto Butantan
- Anti il-11 antibody1 Oct 2026US 2026/0297176 A1
- Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors1 Oct 2026US 2026/0297646 A1Cardiff Oncology, Inc.
- Novel blood biomarker gulp1 for diagnosing liver cancer and use thereof1 Oct 2026US 2026/0297681 A1Ajou University Industry-Academic Cooperation Foundation
Most cited
By later US patents
- Antibodies to human programmed death receptor PD-1454US 8,354,509 B2MSD Oss B.V. · 2013
- Antibodies to human programmed death receptor PD-1151US 8,900,587 B2Merck Sharp & Dohme Corp. · 2014
- Methods for eliciting or enhancing reactivity to HER-2/neu protein131US 5,869,445 AUniversity of Washington · 1999
- Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated114US 5,801,005 AUniversity of Washington · 1998
- Antibodies to human programmed death receptor PD-1107US 8,952,136 B2Merck Sharp & Dohme Corp. · 2015